Ventyx Biosciences' Tamuzimod Shows Promising Long-Term Efficacy in Ulcerative Colitis Phase 2 Trial
Key Insights
Ventyx Biosciences presented 52-week data from its Phase 2 trial of tamuzimod (VTX002) in ulcerative colitis (search) at UEG Week 2024, showcasing sustained efficacy.
The data reinforce tamuzimod's potential as a best-in-class S1P1R (search) modulator with a favorable safety profile among oral ulcerative colitis (search) therapies.
High rates of clinical remission and endoscopic remission suggest tamuzimod could serve as a foundational therapy in future combination treatments for ulcerative colitis (search).
Ventyx Biosciences announced new 52-week data from the Phase 2 trial of tamuzimod (VTX002) in patients with moderately to severely active ulcerative colitis (search). The results, presented at the United European Gastroenterology (UEG) Week meeting in Vienna, Austria, highlight the sustained efficacy and favorable safety profile of the oral S1P1R (search) modulator.
The long-term extension data demonstrated continued clinical and endoscopic remission rates, suggesting a durable treatment effect. "These 52-week data continue to reinforce the potential best-in-class profile of our S1P1R (search) modulator tamuzimod in ulcerative colitis (search)," said Raju Mohan, PhD, Chief Executive Officer of Ventyx Biosciences. He also noted the potential for tamuzimod to be a "backbone of future combination therapies for UC" due to its safety profile compared to other oral options.
Key Findings from the Phase 2 Trial
The Phase 2 trial evaluated the efficacy and safety of tamuzimod in patients with ulcerative colitis (search) over a 52-week period. Key highlights from the presented data include:
- Sustained clinical remission rates
- Continued endoscopic remission
- A safety profile that positions tamuzimod as potentially best-in-disease among oral UC therapies
Silvio Danese, MD, PhD, from the Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy, presented the data at the conference. The presentation slides are available on Ventyx Biosciences' website.
About Tamuzimod (VTX002)
Tamuzimod is an oral, selective S1P1R (search) modulator being developed by Ventyx Biosciences for the treatment of ulcerative colitis (search) and other inflammatory diseases. The company believes that tamuzimod's differentiated profile, including its potential for improved safety and efficacy, could address significant unmet needs in the treatment of ulcerative colitis.
Ulcerative Colitis: An Unmet Need
Ulcerative colitis (search) is a chronic inflammatory bowel disease (IBD) that affects the large intestine. Characterized by inflammation and ulceration of the colon, UC can cause symptoms such as abdominal pain, diarrhea, and rectal bleeding. Current treatment options include anti-inflammatory drugs, immunosuppressants, and biologics. However, many patients do not respond adequately to these therapies, and there remains a need for new and effective treatments, particularly oral therapies with favorable safety profiles.